Mazdutide
Also called IBI362, LY3305677
A dual GLP-1 and glucagon agonist.
This one has been through full clinical trials and is an approved medicine somewhere in the world. The ranges below are drawn from those trials and from what the community reports using.
China · NMPA · Mazdutide · weight management / type 2 diabetes
- Fat loss & metabolic
The quick answer
A dual GLP-1 and glucagon agonist. The glucagon arm is the interesting half - where GLP-1 reduces what goes in, glucagon raises what gets spent and pulls fat out of the liver. Approved in China; not approved in the US, EU or Canada.
What it is not
Not a stronger semaglutide. Different second lever, different profile.
Why people use it
Weight and metabolic effects, with the glucagon arm adding energy expenditure rather than only appetite suppression.
What people report using
These are ranges other people have reported running. They are here so you can see what has actually been done — they are not medical advice and not a recommendation for you.
People report running this anywhere from 4mg to 6mg, once weekly.Where somebody sits in that range depends on what they are using it for and what they are starting from — the low end is a deliberate choice a lot of people make, not a half-hearted version of the high end.
Fat loss & metabolic
- How often
- Once weekly
- Route
- subcutaneous
- Where this comes from
- Approved medicine
Community reporting is thin in English compared with semaglutide and tirzepatide, so treat individual accounts as individual accounts.
What to expect, and when
Trial data runs 48 weeks and beyond. Community-reported timelines are too sparse to pattern reliably; what exists follows the shape of the other GLP-1s - appetite in the first weeks, weight over months.
Side effects, and what people do about them
GI effects in the usual pattern, plus the increased heart rate that tends to come with glucagon agonism.
Go deeper
Open these only if you want them.
How it actually works
GLP-1 and glucagon receptor dual agonist.
More on the evidence
GLP-1/glucagon dual agonist. Phase 3 completed in China. VERIFY current approval status.
What people report, in full
Western community experience with mazdutide is genuinely limited, and it is worth saying that plainly rather than filling the gap. Most of what exists comes from people who sought it out specifically for the glucagon arm - the third mechanism the others do not have, which raises energy expenditure rather than only suppressing appetite. Those reports describe feeling warmer and describe appetite suppression as somewhat less blunt than semaglutide, but there are not many of them and they are not from long runs.
The other recurring point is regional: it was developed and approved in China, which means the trial base and the real-world use base are largely Chinese and the discussion in English-language communities is mostly people reading that data rather than reporting on themselves. Anyone comparing notes here should know they are comparing a thin record to a thick one, not two equal ones.
Sources and review
This record is built on what the wider community reports doing and experiencing, summarised above. No counted dataset has been attached to this compound yet — when one is published, it goes here with its numbers.
These references were located by literature search and recorded as the primary sources behind this record. The publishers block automated retrieval, so they are pointers to the right papers rather than quotations we have checked line by line. They are replaced as we read them properly.
Last reviewed 2026-09-08.
People also look at
Still not sure?
Ask it the way you would ask a person. Follow-up questions are the point — it remembers what you already said.
Ask about Mazdutide